Lawrence Leiter

List of Articles by Year in descending order

Source: //exaly.com/author-pdf/2893346/publications.pdf

Version: 2025-02-01

379 peer-reviewed articles	53,415 peer-reviewed citations	2990 91 peer-reviewed h-index	451341 4.47 score
398 documents	60888 doc citations	3687 95 h-index	80909 citing authors

#	Article	IF	Citations
1	SLICE-CEA CardioLink-8: A Randomized Trial of Evolocumab on Carotid Artery Atherosclerotic Plaque Characteristics in Asymptomatic High-Risk Carotid Stenosis. Circulation, 2025, 151, 351-355.	13.1	9
2	Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2024, 10, 279-288.	2.6	16
3	Real-World Risk of Recurrent Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with LDL-C Above Guideline-Recommended Threshold: A Retrospective Observational Study. Cardiology and Therapy, 2024, 13, 205-220.	1.9	5
4	Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level intervention. Atherosclerosis, 2024, 391, 117472.	1.9	7
5	Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovascular Research, 2024, 120, 1400-1410.	5.7	91
6	Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION	3.2	24
7	Effects of Inclisiran in Patients With Atherosclerotic Cardiovascular Disease. Mayo Clinic Proceedings, 2024, 99, 1222-1235.	1.9	23
8	Epidemiology and Burden of Peripheral Artery Disease in People With Type 2 Diabetes: A Systematic Literature Review. Diabetes Therapy, 2024, 15, 1893-1961.	2.2	37
9	The Diabetes Technology Society Error Grid and Trend Accuracy Matrix for Glucose Monitors. Journal of Diabetes Science and Technology, 2024, 18, 1346-1361.	2.2	44
10	Effects of Extracted Pulse Proteins on Lipid Targets for Cardiovascular Risk Reduction: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 2024, 16, 3765.	3.2	3
11	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. Journal of Diabetes Science and Technology, 2023, 17, 1226-1242.	2.2	254
12	Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial. Circulation, 2023, 147, 284-295.	13.1	35
13	EFFICACY AND SAFETY OF INCLISIRAN BY BASELINE BODY MASS INDEX: A POST HOC POOLED ANALYSIS OF THE ORION-9, ORION-10 AND ORION-11 PHASE III RANDOMIZED CONTROLLED TRIALS. American Journal of Preventive Cardiology, 2023, 13, 100403.	1.5	0
14	Combination of Multiple Low-Risk Lifestyle Behaviors and Incident Type 2 Diabetes: A Systematic Review and Dose-Response Meta-analysis of Prospective Cohort Studies. Diabetes Care, 2023, 46, 643-656.	5.6	64
15	Rationale, Design and Participants Baseline Characteristics of a Crossover Randomized Controlled Trial of the Effect of Replacing SSBs with NSBs versus Water on Glucose Tolerance, Gut Microbiome and Cardiometabolic Risk in Overweight or Obese Adult SSB Consumer: Strategies to Oppose SUGARS with Non-Nutritive Sweeteners or Water (STOP Sugars NOW) Trial and Ectopic Fat Sub-Study. Nutrients, 2023, 15, 1238.	3.2	15
16	Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome. American Journal of Preventive Cardiology, 2023, 15, 100510.	1.5	7
17	Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11. American Journal of Preventive Cardiology, 2023, 14, 100503.	1.5	20
18	P24-046-23 Substitution of Sweetened Soymilk for Unsweetened Cow's Milk and Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Feeding Trials. Current Developments in Nutrition, 2023, 7, 100337.	0.3	0

#	Article	IF	Citations
19	P22-010-23 Coronary Heart Effectiveness Assessment of the Portfolio Diet in Primary Care (CHEAP) Trial: Protocol for a Randomized Controlled Trial. Current Developments in Nutrition, 2023, 7, 101714.	0.3	2
20	Evaluation of the efficacy and safety of bempedoic acid in women and men: Pooled analyses from phase 3 trials. Atherosclerosis, 2023, 384, 117192.	1.9	10
21	Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials. Atherosclerosis, 2023, 386, 117354.	1.9	15
22	Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial. European Heart Journal, 2022, 43, 2958-2967.	2.6	66
23	Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial. Diabetes, Obesity and Metabolism, 2022, 24, 332-336.	3.2	7
24	Validating the NIH LDL-C equation in a specialized lipid cohort: Does it add up?. Clinical Biochemistry, 2022, 99, 60-68.	1.2	22
25	Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial. Diabetes, Obesity and Metabolism, 2022, 24, 704-712.	3.2	15
26	Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. Diabetes Care, 2022, 45, 938-946.	5.6	35
27	Response to the Letter on “The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus”. Cardiovascular Drugs and Therapy, 2022, 36, 573-573.	1.2	3
28	Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. Diabetes Care, 2022, 45, e27-e29.	5.6	17
29	Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. Diabetes, Obesity and Metabolism, 2022, 24, 868-880.	3.2	59
30	Association of Low- and No-Calorie Sweetened Beverages as a Replacement for Sugar-Sweetened Beverages With Body Weight and Cardiometabolic Risk. JAMA Network Open, 2022, 5, e222092.	5.2	152
31	Balance of benefit and risk of ticagrelor in patients with diabetes and stable coronary artery disease according to bleeding risk assessment with the CRUSADE score: Data from THEMIS and THEMIS PCI. American Heart Journal, 2022, 249, 23-33.	1.8	1
32	Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes, Obesity and Metabolism, 2022, 24, 1288-1299.	3.2	57
33	Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. Journal of Clinical Lipidology, 2022, 16, 286-297.	2.6	37
34	Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3448-e3454.	3.1	4
35	Cost–effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 777-785.	2.6	7
36	Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, 2022, 145, 1581-1591.	13.1	26

#	Article	IF	Citations
37	Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6. Stroke, 2022, 53, 2749-2757.	4.4	86
38	Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial. Diabetes, Obesity and Metabolism, 2022, 24, 1998-2007.	3.2	4
39	Lixilan ONE CAN: Randomisierte Studie zum Vergleich eines täglichen vs. wöchentlichen Titrationsalgorithmus für den Wechsel von Basalinsulin zur Fixkombination iGlarLixi bei Typ-2-Diabetespatienten in Kanada. Diabetologie Und Stoffwechsel, 2022, 17, S28-S29.	0.1	0
40	Important Food Sources of Fructose-Containing Sugars and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Controlled Trials. Nutrients, 2022, 14, 2846.	3.2	49
41	Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. Expert Review of Cardiovascular Therapy, 2022, 20, 609-625.	1.2	24
42	Relation of Change or Substitution of Low- and No-Calorie Sweetened Beverages With Cardiometabolic Outcomes: A Systematic Review and Meta-analysis of Prospective Cohort Studies. Diabetes Care, 2022, 45, 1917-1930.	5.6	70
43	Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial. European Journal of Heart Failure, 2022, 24, 1805-1812.	5.0	40
44	Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. European Heart Journal, 2022, 43, 5047-5057.	2.6	113
45	Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials. Cardiovascular Drugs and Therapy, 2022, 38, 493-503.	1.2	31
46	Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers. Diabetes Therapy, 2022, 14, 377-386.	2.2	0
47	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. European Heart Journal, 2021, 42, 2565-2573.	2.6	24
48	Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58. European Journal of Heart Failure, 2021, 23, 1026-1036.	5.0	56
49	Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. Cardiovascular Research, 2021, 117, 284-291.	5.7	75
50	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine, 2021, 384, 117-128.	26.4	1,691
51	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2021, 384, 129-139.	26.4	1,072
52	Does management of lipid lowering differ between specialists and primary care: Insights from GOAL Canada. International Journal of Clinical Practice, 2021, 75, .	0.7	6
53	Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58. Diabetes, Obesity and Metabolism, 2021, 23, 29-38.	3.2	48
54	Co-administration of viscous fiber, Salba-chia and ginseng on glycemic management in type 2 diabetes: a double-blind randomized controlled trial. European Journal of Nutrition, 2021, 60, 3071-3083.	2.7	13

#	Article	IF	Citations
55	The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. Diabetes, Obesity and Metabolism, 2021, 23, 1020-1029.	3.2	31
56	Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey. Canadian Journal of Diabetes, 2021, 45, 743-749.	1.1	2
57	Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1345-1351.	3.1	23
58	Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. Journal of the American College of Cardiology, 2021, 77, 1182-1193.	0.7	223
59	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Diabetes Care, 2021, 44, 1159-1167.	5.6	32
60	Causes and Risk Factors for Death in Diabetes. Journal of the American College of Cardiology, 2021, 77, 1837-1840.	0.7	42
61	From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes. Cardiovascular Diabetology, 2021, 20, .	8.1	51
62	Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. European Heart Journal, 2021, 42, 2995-3007.	2.6	32
63	Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. Journal of the American College of Cardiology, 2021, 77, 2366-2377.	0.7	20
64	Different Food Sources of Fructose-Containing Sugars and Fasting Blood Uric Acid Levels: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. Journal of Nutrition, 2021, 151, 2409-2421.	2.3	22
65	Important Food Sources of Fructose-Containing Sugars and Adiposity: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. Current Developments in Nutrition, 2021, 5, 1017.	0.3	2
66	Important Food Sources of Fructose-Containing Sugars and Fasting Serum Uric Acid Levels: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. Current Developments in Nutrition, 2021, 5, 1011.	0.3	0
67	Important Food Sources of Fructose-Containing Sugars and Blood Pressure: A Systematic Review and Meta-Analysis of Controlled Trials. Current Developments in Nutrition, 2021, 5, 1056.	0.3	1
68	Time to Cardiovascular Benefits of Empagliflozin: A Post Hoc Observation from the EMPA-REG OUTCOME Trial. ESC Heart Failure, 2021, 8, 2603-2607.	1.9	17
69	Effect of Important Food Sources of Fructose-Containing Sugars on Biomarkers of Inflammation: A Systematic Review and Meta-Analysis of Controlled Trials. Current Developments in Nutrition, 2021, 5, 1083.	0.3	0
70	Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2058-2066.	3.2	105
71	Effect of Important Food Sources of Fructose-Containing Sugars on Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Controlled Trials. Current Developments in Nutrition, 2021, 5, 1052.	0.3	0
72	Effect of Intermittent Fasting Strategies on Cardiometabolic Risk Factors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Current Developments in Nutrition, 2021, 5, 1091.	0.3	1

#	Article	IF	Citations
73	Rationale, Design and Baseline Characteristics for the Strategies to Oppose SUGARS With Non-nutritive Sweeteners or Water (STOP Sugars NOW) Trial. Current Developments in Nutrition, 2021, 5, 1012.	0.3	0
74	Important Food Sources of Fructose-Containing Sugars and Postprandial Lipids: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. Current Developments in Nutrition, 2021, 5, 1010.	0.3	0
75	Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease. JACC: Cardiovascular Imaging, 2021, 14, 1164-1173.	3.9	83
76	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care, 2021, 44, 1805-1815.	5.6	100
77	Treatment Inertia in Patients With Familial Hypercholesterolemia. Journal of the American Heart Association, 2021, 10, .	3.1	12
78	Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes. JAMA Cardiology, 2021, 6, 801.	8.4	49
79	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 484-490.	12.4	50
80	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Canadian Journal of Cardiology, 2021, 37, 1129-1150.	1.4	743
81	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. Annals of Internal Medicine, 2021, 174, 1065-1072.	7.3	60
82	Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. Stroke, 2021, 52, 2494-2501.	4.4	24
83	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care, 2021, 44, 2573-2581.	5.6	25
84	A randomized trial of icosapent ethyl in ambulatory patients with COVID-19. IScience, 2021, 24, 103040.	2.4	27
85	Cardiovascular risk factor management in patients with diabetes: Does management differ with disease duration?. Journal of Diabetes and Its Complications, 2021, 35, 107997.	1.8	3
86	Neutrophil-to-lymphocyte ratio predicts cardiovascular events in patients with type 2 diabetes: post hoc analysis of SUSTAIN 6 and PIONEER 6. European Heart Journal, 2021, 42, .	2.6	4
87	The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. Cardiovascular Drugs and Therapy, 2021, 36, 561-567.	1.2	37
88	Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial. Circulation: Cardiovascular Interventions, 2021, 14, .	3.2	3
89	Efficacy and safety of inclisiran in patients with polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised controlled trials. European Heart Journal, 2021, 42, .	2.6	1
90	459 Evaluation of LDL-C reductions by siRNA treatment with inclisiran in patients with diabetes mellitus, metabolic syndrome or neither. European Heart Journal Supplements, 2021, 23, .	0.2	1

#	Article	IF	Citations
91	A LEADER in the management of type 2 diabetes and cardiorenal disease. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 978-984.	2.2	2
92	Alirocumab efficacy and safety by body mass index: A pooled analysis from 10 Phase 3 ODYSSEY trials. Diabetes and Metabolism, 2020, 46, 280-287.	2.7	6
93	Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials. Diabetic Medicine, 2020, 37, 256-266.	1.7	3
94	Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. European Journal of Preventive Cardiology, 2020, 27, 593-603.	1.5	331
95	Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation, 2020, 141, 704-707.	13.1	336
96	Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. American Heart Journal, 2020, 221, 60-66.	1.8	8
97	Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. Mayo Clinic Proceedings, 2020, 95, 77-89.	1.9	147
98	The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 106-114.	12.4	115
99	Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study. Diabetes Care, 2020, 43, 468-475.	5.6	125
100	Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 143-153.	0.9	3
101	Relation of Different Fruit and Vegetable Sources With Incident Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. Journal of the American Heart Association, 2020, 9, .	3.1	166
102	Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. Journal of Clinical Lipidology, 2020, 14, 649-659.e6.	2.6	98
103	Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. JAMA Cardiology, 2020, 5, 1124.	8.4	174
104	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. Cardiovascular Diabetology, 2020, 19, .	8.1	31
105	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation, 2020, 142, 734-747.	13.1	72
106	Association of Major Food Sources of Fructose-Containing Sugars With Incident Metabolic Syndrome. JAMA Network Open, 2020, 3, e209993.	5.2	96
107	Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials. Lancet Diabetes and Endocrinology,the, 2020, 8, 880-893.	12.4	146
108	Bempedoic Acid Efficacy and Safety in High CVD Risk Patients Treated With or Without Ezetimibe: Pooled Analysis of 4 Phase 3 Clinical Trials†. Journal of Clinical Lipidology, 2020, 14, 569-570.	2.6	0

#	Article	IF	Citations
109	Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2020, 36, 596-624.	1.4	523
110	Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. Lancet Diabetes and Endocrinology,the, 2020, 8, 418-435.	12.4	143
111	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurology, The, 2020, 19, 582-590.	13.7	268
112	The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. Nephrology Dialysis Transplantation, 2020, 35, 895-897.	0.7	29
113	Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. New England Journal of Medicine, 2020, 382, 1507-1519.	26.4	1,502
114	Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. New England Journal of Medicine, 2020, 382, 1520-1530.	26.4	773
115	GOAL Canada: Physician Education and Support Can Improve Patient Management. CJC Open, 2020, 2, 49-54.	0.9	11
116	Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis. Metabolism Open, 2020, 7, 100039.	1.8	27
117	Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. European Journal of Preventive Cardiology, 2020, 27, 1663-1674.	1.5	13
118	Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial. Diabetes, Obesity and Metabolism, 2020, 22, 1122-1131.	3.2	21
119	Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. Cardiovascular Diabetology, 2020, 19, .	8.1	28
120	Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. Diabetologia, 2020, 63, 698-710.	4.9	67
121	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. Circulation, 2020, 141, 1227-1234.	13.1	436
122	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus. Circulation, 2020, 141, 843-862.	13.1	106
123	Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data. Clinical Diabetes and Endocrinology, 2020, 6, .	1.5	6
124	Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. Diabetes Care, 2020, 43, 1077-1084.	5.6	34
125	Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. CJC Open, 2020, 2, 402-415.	0.9	9
126	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. Diabetes, Obesity and Metabolism, 2020, 22, 1357-1368.	3.2	34

#	Article	IF	Citations
127	Latest Evidence on Sulfonylureas: What's New?. Diabetes Therapy, 2020, 11, 15-22.	2.2	13
128	OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind. Journal of the Endocrine Society, 2020, 4, .	0.2	0
129	Effect of vegetarian dietary patterns on cardiometabolic risk factors in diabetes: A systematic review and meta-analysis of randomized controlled trials. Clinical Nutrition, 2019, 38, 1133-1145.	3.5	186
130	Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2019, 322, 1780.	14.4	442
131	Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. Cardiovascular Diabetology, 2019, 18, .	8.1	34
132	4945Inclisiran-mediated reductions in Lp(a) in the ORION-1 trial. European Heart Journal, 2019, 40, .	2.6	5
133	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation, 2019, 140, 1693-1702.	13.1	524
134	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 140, 1569-1577.	13.1	141
135	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet, The, 2019, 394, 1169-1180.	46.9	196
136	Ticagrelor in Patients with Stable Coronary Disease and Diabetes. New England Journal of Medicine, 2019, 381, 1309-1320.	26.4	337
137	SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus. Cell Metabolism, 2019, 30, 609-613.	20.8	106
138	Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels. JAMA Cardiology, 2019, 4, 1067.	8.4	163
139	Correctly understanding the diabetes data in FOURIER. Diabetes, Obesity and Metabolism, 2019, 21, 2342-2343.	3.2	0
140	Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovascular Diabetology, 2019, 18, .	8.1	117
141	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, The, 2019, 394, 121-130.	46.9	2,809
142	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet, The, 2019, 394, 131-138.	46.9	569
143	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 606-617.	12.4	640
144	Important food sources of fructose-containing sugars and incident gout: a systematic review and meta-analysis of prospective cohort studies. BMJ Open, 2019, 9, e024171.	1.2	64

#	Article	IF	Citations
145	Efficacy and Safety of Degludec Compared to Glargine 300 Units/mL in Insulin-Experienced Patients With Type 2 Diabetes: Trial Protocol Amendment (NCT03078478). Journal of Diabetes Science and Technology, 2019, 13, 498-506.	2.2	22
146	Residual cardiovascular risk among people with diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 28-38.	3.2	44
147	Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53. Clinical Chemistry, 2019, 65, 781-790.	0.6	11
148	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation, 2019, 139, 2516-2527.	13.1	304
149	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2528-2536.	13.1	496
150	The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight/Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care, 2019, 42, 767-776.	5.6	58
151	Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada. PharmacoEconomics - Open, 2019, 3, 537-550.	1.3	29
152	Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clinical Cardiology, 2019, 42, 498-505.	1.5	27
153	Effects of blood pressure and lipid lowering on cognition. Neurology, 2019, 92, .	0.7	82
154	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2022-2031.	13.1	712
155	4113Glucose lowering drugs or strategies, major adverse cardiovascular events and heart failure outcomes, and association with weight loss - meta-analysis of large cardiovascular outcome trials. European Heart Journal, 2019, 40, .	2.6	0
156	P5364Safety profile of bempedoic acid: pooled analysis of 4 phase 3 clinical trials. European Heart Journal, 2019, 40, .	2.6	0
157	Relation of Total Sugars, Sucrose, Fructose, and Added Sugars With the Risk of Cardiovascular Disease. Mayo Clinic Proceedings, 2019, 94, 2399-2414.	1.9	84
158	Important Food Sources of Fructose-Containing Sugars and Incident Hypertension: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies. Journal of the American Heart Association, 2019, 8, .	3.1	48
159	Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement. Canadian Journal of Diabetes, 2019, 43, 384-391.	1.1	12
160	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2019, 380, 347-357.	26.4	5,861
161	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet, The, 2019, 393, 31-39.	46.9	2,592
162	Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation, 2019, 139, 366-375.	13.1	34

#	Article	IF	Citations
163	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2018, 34, 506-525.	1.4	524
164	Effect of pasta in the context of low-glycaemic index dietary patterns on body weight and markers of adiposity: a systematic review and meta-analysis of randomised controlled trials in adults. BMJ Open, 2018, 8, e019438.	1.2	53
165	Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism: Clinical and Experimental, 2018, 85, 32-37.	8.9	242
166	Metabolic Surgery. Journal of the American College of Cardiology, 2018, 71, 670-687.	0.7	170
167	Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. Diabetes, Obesity and Metabolism, 2018, 20, 1479-1489.	3.2	98
168	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial. American Heart Journal, 2018, 200, 83-89.	1.8	143
169	DECLARE-TIMI 58: Participants' baseline characteristics. Diabetes, Obesity and Metabolism, 2018, 20, 1102-1110.	3.2	105
170	Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal, 2018, 39, 2526-2539.	2.6	346
171	Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial. Diabetology and Metabolic Syndrome, 2018, 10, .	2.5	29
172	Inflammatory and Cholesterol Risk in the FOURIER Trial. Circulation, 2018, 138, 131-140.	13.1	266
173	Insights Into the Current Management of Older Adults With Type 2 Diabetes in the Ontario Primary Care Setting. Canadian Journal of Diabetes, 2018, 42, 23-30.	1.1	17
174	Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey. Canadian Journal of Diabetes, 2018, 42, 130-137.	1.1	26
175	Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes, Obesity and Metabolism, 2018, 20, 889-897.	3.2	279
176	Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials. Diabetic Medicine, 2018, 35, 121-130.	1.7	32
177	The Effect of Small Doses of Fructose and Its Epimers on Glycemic Control: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. Nutrients, 2018, 10, 1805.	3.2	32
178	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, The, 2018, 392, 1519-1529.	46.9	1,681
179	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet, The, 2018, 392, 2269-2279.	46.9	77
180	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. Cmaj, 2018, 190, E1192-E1206.	0.8	52

#	Article	IF	Citations
181	Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Diabetic Medicine, 2018, 35, 1742-1751.	1.7	22
182	Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials. Diabetes, Obesity and Metabolism, 2018, 20, 2389-2398.	3.2	21
183	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes, Obesity and Metabolism, 2018, 20, 2210-2219.	3.2	156
184	The effect of small doses of fructose and allulose on postprandial glucose metabolism in type 2 diabetes: A double-blind, randomized, controlled, acute feeding, equivalence trial. Diabetes, Obesity and Metabolism, 2018, 20, 2361-2370.	3.2	49
185	The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents. Diabetes Research and Clinical Practice, 2018, 143, 1-14.	2.0	50
186	Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics. American Heart Journal, 2018, 203, 30-38.	1.8	85
187	Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE-3 Trial. Journal of the American Heart Association, 2018, 7, .	3.1	2
188	CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management. Canadian Journal of Cardiology, 2018, 34, 1350-1361.	1.4	4
189	Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins. Circulation, 2018, 138, 1304-1316.	13.1	151
190	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. New England Journal of Medicine, 2018, 379, 1107-1117.	26.4	250
191	Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. Circulation, 2018, 138, 1605-1607.	13.1	34
192	Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis, 2018, 277, 195-203.	1.9	391
193	Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W	3.2	176
194	Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. Journal of the American Heart Association, 2017, 6, .	3.1	2
195	Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II. Diabetes, Obesity and Metabolism, 2017, 19, 989-996.	3.2	49
196	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Canadian Journal of Cardiology, 2017, 33, 557-576.	1.4	290
197	A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety. Canadian Journal of Cardiology, 2017, 33, 940-942.	1.4	5
198	Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. CMAJ Open, 2017, 5, E152-E177.	1.4	57

#	Article	IF	Citations
199	Gaps and barriers in the control of blood glucose in people with type 2 diabetes. Diabetes and Vascular Disease Research, 2017, 14, 172-183.	2.1	139
200	Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment. Diabetes, Obesity and Metabolism, 2017, 19, 1594-1601.	3.2	22
201	Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks. Journal of Diabetes and Its Complications, 2017, 31, 1283-1285.	1.8	11
202	Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial. Diabetes and Metabolism, 2017, 43, 453-459.	2.7	27
203	Cross-sectional associations between dietary intake and carotid intima media thickness in type 2 diabetes: baseline data from a randomised trial. BMJ Open, 2017, 7, e015026.	1.2	5
204	A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and apolipoprotein B ,. American Journal of Clinical Nutrition, 2017, 105, 1239-1247.	3.2	100
205	Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. New England Journal of Medicine, 2017, 376, 1430-1440.	26.4	952
206	Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. JAMA Cardiology, 2017, 2, 370.	8.4	169
207	siRNA to PCSK9 in patients with high cardiovascular risk and elevated LDL-C: the ORION 1 trial. Atherosclerosis, 2017, 263, e9-e10.	1.9	1
208	Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 941-950.	12.4	566
209	Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. Diabetes, Obesity and Metabolism, 2017, 19, 1781-1792.	3.2	134
210	Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials. Journal of the American Heart Association, 2017, 6, .	3.1	16
211	Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus. Experimental and Clinical Endocrinology and Diabetes, 2017, 125, 419-435.	0.9	15
212	Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment – a clinical appraisal. Journal of Diabetes and Its Complications, 2017, 31, 1451-1457.	1.8	3
213	Diabetes for Cardiologists: Practical Issues in Diagnosis and Management. Canadian Journal of Cardiology, 2017, 33, 366-377.	1.4	27
214	Effects of Changing the Amount and Source of Dietary Carbohydrates on Symptoms and Dietary Satisfaction Over a 1-Year Period in Subjects with Type 2 Diabetes: Canadian Trial of Carbohydrates in Diabetes (CCD). Canadian Journal of Diabetes, 2017, 41, 164-176.	1.1	11
215	3910SUSTAIN 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes. European Heart Journal, 2017, 38, .	2.6	1
216	Low-glycaemic index diet to improve glycaemic control and cardiovascular disease in type 2 diabetes: design and methods for a randomised, controlled, clinical trial. BMJ Open, 2016, 6, e012220.	1.2	8

#	Article	IF	Citations
217	Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes, Obesity and Metabolism, 2016, 18, 766-774.	3.2	40
218	Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial. Diabetes, Obesity and Metabolism, 2016, 18, 186-190.	3.2	33
219	Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity and Metabolism, 2016, 18, 930-935.	3.2	13
220	Fructose intake and risk of gout and hyperuricemia: a systematic review and meta-analysis of prospective cohort studies. BMJ Open, 2016, 6, e013191.	1.2	109
221	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2009-2020.	26.4	580
222	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2021-2031.	26.4	770
223	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2032-2043.	26.4	345
224	Effects of dietary pulse consumption on body weight: a systematic review and meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition, 2016, 103, 1213-1223.	3.2	190
225	No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. European Heart Journal, 2016, 37, 2981-2989.	2.6	158
226	Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN : ADD TO GLP -1	3.2	31
227	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 1834-1844.	26.4	6,261
228	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology, 2016, 32, 1263-1282.	1.4	872
229	Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: Analysis of pooled events from 19 clinical trials. Journal of Diabetes and Its Complications, 2016, 30, 1378-1384.	1.8	9
230	Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation. Diabetes Research and Clinical Practice, 2016, 112, 50-56.	2.0	13
231	Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin. Diabetes Therapy, 2016, 7, 269-278.	2.2	16
232	LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. Cardiovascular Diabetology, 2016, 15, .	8.1	48
233	Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada survey. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 277-284.	2.3	15
234	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2016, 32, 569-588.	1.4	423

#	Article	IF	Citations
235	Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes and Metabolism, 2016, 42, 25-32.	2.7	118
236	Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. American Journal of Medicine, 2016, 129, 340.e1-340.e8.	1.4	38
237	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. Canadian Journal of Cardiology, 2016, 32, 311-318.	1.4	28
238	Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care, 2015, 38, 696-705.	5.6	154
239	Alirocumab Treatment Effect on Non-HDL-C: Pooled Analyses of 10 Phase 3 Trials in the ODYSSEY Program. Journal of Clinical Lipidology, 2015, 9, 471-472.	2.6	2
240	Identification of educational needs in the management of overweight and obesity: results of an international survey of attitudes and practice. Clinical Obesity, 2015, 5, 245-255.	1.3	10
241	Effect of Replacing Animal Protein with Plant Protein on Glycemic Control in Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 2015, 7, 9804-9824.	3.2	120
242	Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal, 2015, 36, 1012-1022.	2.6	1,303
243	Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus. Circulation, 2015, 132, 2345-2350.	13.1	47
244	Cardiovascular Risk Factors and In-hospital Mortality in Acute Coronary Syndromes: Insights From the Canadian Global Registry of Acute Coronary Events. Canadian Journal of Cardiology, 2015, 31, 1455-1461.	1.4	51
245	Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 2015, 29, 438-444.	1.8	45
246	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2015, 31, 549-568.	1.4	441
247	Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension. Diabetes Care, 2015, 38, 1218-1227.	5.6	165
248	Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial. Diabetes Care, 2015, 38, 1145-1153.	5.6	84
249	Effect of Fructose on Established Lipid Targets: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. Journal of the American Heart Association, 2015, 4, .	3.1	108
250	The effect of a dietary portfolio compared to a DASH-type diet on blood pressure. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 1132-1139.	2.1	38
251	Sugar-sweetened beverage consumption and incident hypertension: a systematic review and meta-analysis of prospective cohorts. American Journal of Clinical Nutrition, 2015, 102, 914-921.	3.2	146
252	Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study. Diabetes Care, 2015, 38, 355-364.	5.6	209

#	Article	IF	Citations
253	Tree Nuts Improve Glycemic Control: A Systematic Review and Meta-Analysis of Randomized Controlled Dietary Trials. FASEB Journal, 2015, 29, .	2.3	0
254	Effect of a Low Glycemic Index Diet on Markers of Oxidative Damage in Type 2 Diabetes. FASEB Journal, 2015, 29, .	2.3	0
255	Effect of Tree Nuts on Glycemic Control in Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Dietary Trials. PLoS ONE, 2014, 9, e103376.	1.5	148
256	Effect of tree nuts on metabolic syndrome criteria: a systematic review and meta-analysis of randomised controlled trials. BMJ Open, 2014, 4, e004660.	1.2	127
257	Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study. Diabetes Care, 2014, 37, 2723-2730.	5.6	92
258	The clinical burden of type 2 diabetes in patients with acute coronary syndromes: Prognosis and implications for short- and long-term management. Diabetes and Vascular Disease Research, 2014, 11, 395-409.	2.1	16
259	Dosing Irregularities and Self-Treated Hypoglycemia in Type 2 Diabetes: Results from the Canadian Cohort of an International Survey of Patients and Healthcare Professionals. Canadian Journal of Diabetes, 2014, 38, 38-44.	1.1	44
260	Profile of adults with type 2 diabetes and uptake of clinical care best practices: Results from the 2011 Survey on Living with Chronic Diseases in Canada – Diabetes component. Diabetes Research and Clinical Practice, 2014, 103, 11-19.	2.0	10
261	Effect of fructose on postprandial triglycerides: A systematic review and meta-analysis of controlled feeding trials. Atherosclerosis, 2014, 232, 125-133.	1.9	161
262	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2014, 30, 485-501.	1.4	229
263	Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro. Diabetes Care, 2014, 37, 2317-2325.	5.6	206
264	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE): 2014 update. Cmaj, 2014, 186, 1299-1305.	0.8	19
265	The Effects of Medical Management on the Progression of Diabetic Retinopathy in Persons with Type 2 Diabetes. Ophthalmology, 2014, 121, 2443-2451.	5.8	315
266	Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. European Journal of Clinical Nutrition, 2014, 68, 416-423.	1.7	278
267	Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with a 28-Week Extension. Journal of the American Geriatrics Society, 2014, 62, 1252-1262.	2.2	164
268	Effect of Lowering the Glycemic Load With Canola Oil on Glycemic Control and Cardiovascular Risk Factors: A Randomized Controlled Trial. Diabetes Care, 2014, 37, 1806-1814.	5.6	83
269	Effect of tree nuts on glycemic control in diabetes: a systematic review and meta-analysis of randomized controlled dietary trials (1025.16). FASEB Journal, 2014, 28, .	2.3	0
270	Tree nuts improve criteria of the metabolic syndrome: a systematic review and meta-analysis of randomized controlled dietary trials (1025.6). FASEB Journal, 2014, 28, .	2.3	1

#	Article	IF	Citations
271	Determinants of lifestyle behavior in type 2 diabetes: results of the 2011 cross-sectional survey on living with chronic diseases in Canada. BMC Public Health, 2013, 13, .	2.1	22
272	Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine, 2013, 369, 1317-1326.	26.4	3,308
273	Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet, The, 2013, 382, 941-950.	46.9	689
274	Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes and Endocrinology,the, 2013, 1, 317-328.	12.4	207
275	Management of Risk Factors Among Ambulatory Patients at High Cardiovascular Risk in Canada: A Follow-up Study. Canadian Journal of Cardiology, 2013, 29, 1586-1592.	1.4	5
276	Survey of Diabetes Care in Patients Presenting With Acute Coronary Syndromes in Canada. Canadian Journal of Cardiology, 2013, 29, 1134-1137.	1.4	3
277	Type 2 Diabetes Mellitus Management in Canada: Is It Improving?. Canadian Journal of Diabetes, 2013, 37, 82-89.	1.1	135
278	Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. Lancet Diabetes and Endocrinology,the, 2013, 1, 123-131.	12.4	38
279	Inflammatory biomarkers CRP, MCP-1, serum amyloid alpha and interleukin-18 in patients with HTN and dyslipidemia: impact of diabetes mellitus on metabolic syndrome and the effect of statin therapy. Hypertension Research, 2013, 36, 550-558.	2.0	24
280	Risks and benefits of intensive blood pressure lowering in patients with type 2 diabetes. Cmaj, 2013, 185, 963-967.	0.8	17
281	A comparison of the assessment and management of cardiometabolic risk in patients with and without type 2 diabetes mellitus in Canadian primary care. Diabetes, Obesity and Metabolism, 2013, 15, 1093-1100.	3.2	17
282	Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus. Archives of Internal Medicine, 2012, 172, 1296.	8.1	125
283	Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. New England Journal of Medicine, 2012, 367, 2089-2099.	26.4	1,962
284	Assessment and Treatment of Cardiometabolic Risk in Adults at Risk for or with Type 2 Diabetes Mellitus. Canadian Journal of Diabetes, 2012, 36, 320-326.	1.1	0
285	The Effects of Fructose Intake on Serum Uric Acid Vary among Controlled Dietary Trials. Journal of Nutrition, 2012, 142, 916-923.	2.3	172
286	Effect of Fructose on Glycemic Control in Diabetes. Diabetes Care, 2012, 35, 1611-1620.	5.6	203
287	Drugs Targeting High-Density Lipoprotein Cholesterol for Coronary Artery Disease Management. Canadian Journal of Cardiology, 2012, 28, 667-677.	1.4	6
288	Effect of Fructose on Body Weight in Controlled Feeding Trials. Annals of Internal Medicine, 2012, 156, 291-304.	7.3	280

#	Article	IF	Citations
289	Greater Dissociation of Apolipoprotein B and LDL Cholesterol Targets in Diabetes Versus Nondiabetes Patients Receiving Lipid-Lowering Therapy. Journal of Clinical Lipidology, 2011, 5, 198-199.	2.6	0
290	Lower LDL-C values Should Be Reached to Normalize Apolipoprotein B Concentrations in Hypertriglyceridemic Patients Receiving Lipid-lowering Therapy. Journal of Clinical Lipidology, 2011, 5, 199-200.	2.6	0
291	Use of a Treatment Optimization Algorithm Involving Statin-Ezetimibe Combination Aids in Achievement of Guideline-Based Low-Density Lipoprotein Targets in Patients With Dyslipidemia at High Vascular Risk Guideline-Based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANC). Canadian Journal of Cardiology, 2011, 27, 138-145.	1.4	6
292	Identification and Management of Cardiometabolic Risk in Canada: A Position Paper by the Cardiometabolic Risk Working Group (Executive Summary). Canadian Journal of Cardiology, 2011, 27, 124-131.	1.4	51
293	Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease. International Journal of Cardiology, 2011, 153, 141-147.	1.6	20
294	ACCORD microvascular and Eye substudy: should the results change our practice?. Diabetes Management, 2011, 1, 389-396.	0.3	0
295	Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes, Obesity and Metabolism, 2011, 13, 615-628.	3.2	77
296	Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabetic Medicine, 2011, 28, 1343-1351.	1.7	88
297	Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes. Diabetes and Vascular Disease Research, 2011, 8, 160-172.	2.1	20
298	Effect of a Dietary Portfolio of Cholesterol-Lowering Foods Given at 2 Levels of Intensity of Dietary Advice on Serum Lipids in Hyperlipidemia. JAMA - Journal of the American Medical Association, 2011, 306, .	14.4	206
299	Relation Between Obesity and the Attainment of Optimal Blood Pressure and Lipid Targets in High Vascular Risk Outpatients. American Journal of Cardiology, 2010, 106, 1270-1276.	1.5	36
300	Attainment of Canadian and European guidelines' lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin. International Journal of Clinical Practice, 2010, 64, 1765-1772.	0.7	4
301	Adding monounsaturated fatty acids to a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. Cmaj, 2010, 182, 1961-1967.	0.8	81
302	Glucose lowering and cardiovascular disease: what do we know and what should we do?. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, s25-s31.	2.2	14
303	Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine, 2010, 362, 1477-1490.	26.4	623
304	Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. New England Journal of Medicine, 2010, 362, 1563-1574.	26.4	2,723
305	Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: The CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) study. Canadian Journal of Cardiology, 2010, 26, 80-86.	1.4	27
306	The incretin system and cardiometabolic disease. Canadian Journal of Cardiology, 2010, 26, 87-95.	1.4	16

#	Article	IF	Citations
307	Prevalence of dyslipidemia in statin-treated patients in Canada: Results of the DYSlipidemia International Study (DYSIS). Canadian Journal of Cardiology, 2010, 26, e330-e335.	1.4	49
308	Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?. Lipids in Health and Disease, 2010, 9, 136.	3.5	24
309	The relation of low glycaemic index fruit consumption to glycaemic control and risk factors for coronary heart disease in type 2 diabetes. Diabetologia, 2010, 54, 271-279.	4.9	111
310	Type 2 Diabetes and TZDs (Thiazolidinediones) Fritz 9.24.09. Journal of Clinical Endocrinology and Metabolism, 2009, 94, E2-E2.	3.1	0
311	Applying the Evidence. Stroke, 2009, 40, 1417-1424.	4.4	65
312	Cardiovascular risk and glycemic control. Cmaj, 2009, 180, 907-908.	0.8	4
313	Role of Renin-Angiotensin System Blockade in Patients With Diabetes Mellitus. American Journal of Cardiology, 2009, 104, 835-839.	1.5	39
314	Usefulness of Statin–Ezetimibe Combination to Reduce the Care Gap in Dyslipidemia Management in Patients With a High Risk of Atherosclerotic Disease. American Journal of Cardiology, 2009, 104, 798-804.e2.	1.5	16
315	Diabetes and cardiovascular disease: The role of glycemic control. Current Diabetes Reports, 2009, 9, 65-72.	4.1	11
316	Viscosity of fiber preloads affects food intake in adolescents. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 498-503.	2.1	69
317	Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. American Heart Journal, 2009, 158, 896-901.e3.	1.8	186
318	Effect of Ezetimibe Added to Atorvastatin on Lipoprotein Subclass Cholesterol Content in Patients with Higher Versus Lower Triglyceride Levels. Journal of Clinical Lipidology, 2009, 3, 224-225.	2.6	1
319	Hypertension in diabetes: A call to action. Canadian Journal of Cardiology, 2009, 25, 299-302.	1.4	34
320	Confirming the critical importance of blood pressure control in people with diabetes. Canadian Journal of Cardiology, 2009, 25, 594-595.	1.4	0
321	Efficacy and safety of ursodeoxycholic acid in primary, type IIa or IIb hypercholesterolemia: A multicenter, randomized, double-blind clinical trial. Atherosclerosis, 2009, 203, 479-482.	1.9	11
322	Diabetes de Tipo 2 y las TZD (Tiazolidinedionas) Fritz 9.24.09. Journal of Clinical Endocrinology and Metabolism, 2009, 94, E1-E1.	3.1	0
323	Discordance Between Physicians' Estimation of Patient Cardiovascular Risk and Use of Evidence-Based Medical Therapy. American Journal of Cardiology, 2008, 102, 1142-1145.	1.5	24
324	Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease††Conflicts of interest: Dr. Conard served as a consultant and advisor for Merck & Company and Merck/Schering-Plough. Dr. Bays received research grants from Amylin, San Diego, California, Amgen, Thousand Oaks, California, J&J, Langhorne, Pennsylvania, Aegerion, Bridgewater, New Jersey, Abbott, Chicago, Illin. American Journal of Cardiology, 2008, 102, 1489-1494.	1.5	84

#	Article	IF	Citations
325	Efficacy and Safety of Ezetimibe Added on to Atorvastatin (40 mg) Compared With Uptitration of Atorvastatin (to 80 mg) in Hypercholesterolemic Patients at High Risk of Coronary Heart Disease. American Journal of Cardiology, 2008, 102, 1495-1501.	1.5	87
326	Lipid management in cardiovascular disease prevention guidelines: Strategies and tactics for implementation. Atherosclerosis, 2008, 196, 532-541.	1.9	14
327	How many cardiovascular events can be prevented with optimal management of high-risk Canadians?. Canadian Journal of Cardiology, 2008, 24, 363-368.	1.4	6
328	Low Socioeconomic Status and Absence of Supplemental Health Insurance as Barriers to Diabetes Care Access and Utilization. Canadian Journal of Diabetes, 2008, 32, 174-181.	1.1	18
329	Nutritional Considerations for Older Adults With Type 2 Diabetes. Journal of Nutrition in Gerontology and Geriatrics, 2008, 27, 363-380.	0.6	4
330	Long Term Effectiveness of A Dietary Portfolio of Cholesterol-Lowering Foods in Hypercholesterolemic Subjects. FASEB Journal, 2008, 22, .	2.3	0
331	Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: A substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. American Heart Journal, 2007, 153, 881-888.	1.8	86
332	Efficacy and safety of rosuvastatin 40mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. Atherosclerosis, 2007, 194, e154-e164.	1.9	49
333	Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?. Expert Opinion on Pharmacotherapy, 2007, 8, 1615-1628.	1.9	30
334	Title is missing!. Canadian Journal of Cardiology, 2007, 23, 398.	1.4	0
335	Five batches representative of Ontario-grown American ginseng root produce comparable reductions of postprandial glycemia in healthy individualsThis article is one of a selection of papers published in this special issue (part 1 of 2) on the Safety and Efficacy of Natural Health Products.. Canadian Journal of Physiology and Pharmacology, 2007, 85, 856-864.	1.4	20
336	Tumor necrosis factor α −238G>A genotype alters postprandial plasma levels of free fatty acids in obese individuals with type 2 diabetes mellitus. Metabolism: Clinical and Experimental, 2007, 56, 649-655.	8.9	37
337	Metabolic syndrome under fire: Weighing in on the truth. Canadian Journal of Cardiology, 2006, 22, 379-382.	1.4	14
338	Optimal care of cardiovascular disease and type 2 diabetes patients: Shared responsibilities between the cardiologist and diabetologist. Atherosclerosis Supplements, 2006, 7, 37-42.	3.1	9
339	Effects of l-Tryptophan on Food Intake and Selection in Lean Men and Women. Annals of the New York Academy of Sciences, 2006, 499, 327-328.	2.6	0
340	Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Current Opinion in Cardiology, 2006, 21, 400-404.	1.0	62
341	The Editor's Roundtable: Diabetes Mellitus and Coronary Heart Disease. American Journal of Cardiology, 2006, 98, 842-856.	1.5	4
342	Can thiazolidinediones delay disease progression in type 2 diabetes?. Current Medical Research and Opinion, 2006, 22, 1193-1201.	1.4	13

#	Article	IF	Citations
343	Long-Term Intake of North American Ginseng Has No Effect on 24-Hour Blood Pressure and Renal Function. Hypertension, 2006, 47, 791-796.	4.7	51
344	beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes. Diabetic Medicine, 2005, 22, 963-972.	1.7	47
345	North American Ginseng Exerts a Neutral Effect on Blood Pressure in Individuals With Hypertension. Hypertension, 2005, 46, 406-411.	4.7	76
346	Review: Defining the role of statins in diabetes. British Journal of Diabetes and Vascular Disease, 2005, 5, 55-62.	0.6	3
347	Perindopril in diabetes: perspective from the EUROPA substudy, PERSUADEThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2005, 26, 1347-1349.	2.6	20
348	Diabetic dyslipidaemia: Effective management reduces cardiovascular risk. Atherosclerosis Supplements, 2005, 6, 37-43.	3.1	4
349	Postprandial glucose regulation: New data andnew implications. Clinical Therapeutics, 2005, 27, S42-S56.	1.9	148
350	The prevention of diabetic microvascular complications of diabetes: Is there a role for lipid lowering?. Diabetes Research and Clinical Practice, 2005, 68, S3-S14.	2.0	89
351	Of the renin-angiotensin system and reactive oxygen speciesType 2 diabetes and angiotensin II inhibition. American Journal of Hypertension, 2005, 18, 121-128.	1.0	100
352	Ongoing clinical trials of the pleiotropic effects of statins. Vascular Health and Risk Management, 2005, 1, 29-40.	3.1	42
353	Rosuvastatin. Journal of Drug Evaluation, 2004, 2, 41-55.	0.1	1
354	How does the prognosis of diabetes compare with that of established vascular disease? Insights from the Canadian Vascular Protection (VP) Registry. American Heart Journal, 2004, 148, 1028-1033.	1.8	16
355	Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia. European Journal of Clinical Nutrition, 2003, 57, 243-248.	1.7	72
356	Effects of a Dietary Portfolio of Cholesterol-Lowering Foods vs Lovastatin on Serum Lipids and C-Reactive Protein. JAMA - Journal of the American Medical Association, 2003, 290, 502.	14.4	548
357	Lipids and Diabetes Mellitus: A Review of Therapeutic Options. Current Medical Research and Opinion, 2002, 18, s58-s74.	1.4	3
358	Effects of high- and low-isoflavone soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and women. American Journal of Clinical Nutrition, 2002, 76, 365-372.	3.2	290
359	A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis, 2002, 162, 201-210.	1.9	20
360	High-protein diets in hyperlipidemia: effect of wheat gluten on serum lipids, uric acid, and renal function. American Journal of Clinical Nutrition, 2001, 74, 57-63.	3.2	104

#	Article	IF	Citations
361	Simple skinfold-thickness measurements complement conventional anthropometric assessments in predicting glucose tolerance. American Journal of Clinical Nutrition, 2001, 73, 567-573.	3.2	41
362	Polycystic Ovary Syndrome and Insulin Resistance: New Approaches to Management, including Exercise. Journal of Obstetrics and Gynaecology Canada, 2001, 23, 306-312.	0.1	2
363	Use of the Statins in Patients After Acute Myocardial Infarction. Archives of Internal Medicine, 2001, 161, 183.	8.1	59
364	Time of day and glucose tolerance status affect serum short-chain fatty concentrations in humans. Metabolism: Clinical and Experimental, 1997, 46, 805-811.	8.9	94
365	Combination therapy with oral antihyperglycemic agents in the treatment of non-insulin-dependent diabetes mellitus. Trends in Endocrinology and Metabolism, 1996, 7, 216-218.	8.0	1
366	Use of bioelectrical impedance analysis measurements in patients with diabetes. The Diabetes Control and Complications Trial Research Group. American Journal of Clinical Nutrition, 1996, 64, 515S-518S.	3.2	12
367	Retinopathy and Neuropathy Associated With Complete Apolipoprotein A-I Deficiency. American Journal of the Medical Sciences, 1996, 312, 30-33.	0.3	1
368	Retinopathy and Neuropathy Associated With Complete Apolipoprotein A-I Deficiency. American Journal of the Medical Sciences, 1996, 312, 30-33.	0.3	19
369	Metabolic Responses to Intense Exercise in Lean and Obese Subjects*. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 438-445.	3.1	41
370	Obesity: overview of pathogenesis and treatment. Canadian Journal of Physiology and Pharmacology, 1986, 64, 814-817.	1.4	1
371	Effects of L-tryptophan on short term food intake in lean men. Nutrition Research, 1985, 5, 595-607.	1.8	65
372	Survival During Fasting May Depend on Fat as Well as Protein Stores. JAMA - Journal of the American Medical Association, 1982, 248, 2306.	14.4	107
373	Type 2 diabetes - treat early, treat intensively. International Journal of Clinical Practice, 0, 61, 16-21.	0.7	18
374	Food sources of fructose-containing sugars and glycaemic control: systematic review and meta-analysis of controlled intervention studies. BMJ: British Medical Journal, 0, , k4644.	0.1	121
375	Albiglutide and atrial fibrillation in patients with Type 2 diabetes and established cardiovascular disease: insights from the Harmony Outcomes trial. European Journal of Preventive Cardiology, 0, 33, 30-41.	1.5	6
376	Efficacy and safety of inclisiran based on background lipid-lowering treatment. European Journal of Preventive Cardiology, 0, , .	1.5	7
377	Optimizing low-density lipoprotein cholesterol (LDL-C) management – a US physician survey of barriers and burdens. American Journal of Preventive Cardiology, 0, 25, 101386.	1.5	2
378	Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled Trial. Circulation: Heart Failure, 0, 19, .	2.7	1

#	Article	IF	Citations
379	Inclisiran in Patients with CKD. Journal of the American Society of Nephrology: JASN, 0, 37, 1497-1506.	0.2	4